Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Galmed shares surged after announcing a new brain-penetrating formulation for treating Parkinson's.
Galmed Pharmaceuticals shares surged after announcing a new brain-penetrating formulation of its drug Aramchol.
Developed with Barcode Nanotech, this innovation uses lipid nanoparticles to cross the blood-brain barrier, potentially treating Parkinson's disease and dementia.
Preclinical studies showed the drug reduces alpha-synuclein aggregation, and the company plans to begin clinical trials in 2026.
3 Articles
Las acciones de Galmed se dispararon después de anunciar una nueva formulación de penetración cerebral para el tratamiento del Parkinson.